nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—CYP3A4—type 2 diabetes mellitus	0.316	1	CbGaD
Tadalafil—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0506	0.152	CbGbCtD
Tadalafil—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0451	0.136	CbGbCtD
Tadalafil—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0412	0.124	CbGbCtD
Tadalafil—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.036	0.109	CbGbCtD
Tadalafil—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0326	0.0982	CbGbCtD
Tadalafil—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0247	0.0744	CbGbCtD
Tadalafil—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0237	0.0713	CbGbCtD
Tadalafil—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0237	0.0713	CbGbCtD
Tadalafil—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0224	0.0675	CbGbCtD
Tadalafil—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0167	0.0503	CbGbCtD
Tadalafil—CYP3A4—Losartan—type 2 diabetes mellitus	0.0153	0.046	CbGbCtD
Tadalafil—PDE5A—penis—type 2 diabetes mellitus	0.0109	0.372	CbGeAlD
Tadalafil—PDE5A—artery—type 2 diabetes mellitus	0.00505	0.172	CbGeAlD
Tadalafil—PDE5A—endothelium—type 2 diabetes mellitus	0.00426	0.145	CbGeAlD
Tadalafil—PDE11A—liver—type 2 diabetes mellitus	0.00285	0.0973	CbGeAlD
Tadalafil—PDE5A—retina—type 2 diabetes mellitus	0.00207	0.0707	CbGeAlD
Tadalafil—PDE5A—cardiovascular system—type 2 diabetes mellitus	0.00175	0.0598	CbGeAlD
Tadalafil—PDE5A—adipose tissue—type 2 diabetes mellitus	0.00155	0.0528	CbGeAlD
Tadalafil—CYP3A4—kidney—type 2 diabetes mellitus	0.000535	0.0183	CbGeAlD
Tadalafil—CYP3A4—liver—type 2 diabetes mellitus	0.000338	0.0115	CbGeAlD
Tadalafil—Chest pain—Metformin—type 2 diabetes mellitus	0.000148	0.000605	CcSEcCtD
Tadalafil—Myalgia—Metformin—type 2 diabetes mellitus	0.000148	0.000605	CcSEcCtD
Tadalafil—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000147	0.000602	CcSEcCtD
Tadalafil—Headache—Pioglitazone—type 2 diabetes mellitus	0.000147	0.000602	CcSEcCtD
Tadalafil—Syncope—Irbesartan—type 2 diabetes mellitus	0.000147	0.000601	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000147	0.000601	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000146	0.000598	CcSEcCtD
Tadalafil—Discomfort—Metformin—type 2 diabetes mellitus	0.000146	0.000598	CcSEcCtD
Tadalafil—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000146	0.000598	CcSEcCtD
Tadalafil—Nausea—Glipizide—type 2 diabetes mellitus	0.000146	0.000596	CcSEcCtD
Tadalafil—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000145	0.000595	CcSEcCtD
Tadalafil—Hypotension—Valsartan—type 2 diabetes mellitus	0.000145	0.000595	CcSEcCtD
Tadalafil—Vision blurred—Losartan—type 2 diabetes mellitus	0.000145	0.000595	CcSEcCtD
Tadalafil—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000145	0.000593	CcSEcCtD
Tadalafil—Pain—Gliclazide—type 2 diabetes mellitus	0.000145	0.000593	CcSEcCtD
Tadalafil—Constipation—Gliclazide—type 2 diabetes mellitus	0.000145	0.000593	CcSEcCtD
Tadalafil—Rash—Glimepiride—type 2 diabetes mellitus	0.000144	0.00059	CcSEcCtD
Tadalafil—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000144	0.00059	CcSEcCtD
Tadalafil—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000144	0.000589	CcSEcCtD
Tadalafil—Rash—Sitagliptin—type 2 diabetes mellitus	0.000144	0.000588	CcSEcCtD
Tadalafil—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000144	0.000588	CcSEcCtD
Tadalafil—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000144	0.000588	CcSEcCtD
Tadalafil—Headache—Glimepiride—type 2 diabetes mellitus	0.000143	0.000586	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.000143	0.00182	CbGpPWpGaD
Tadalafil—Cough—Irbesartan—type 2 diabetes mellitus	0.000143	0.000585	CcSEcCtD
Tadalafil—Headache—Sitagliptin—type 2 diabetes mellitus	0.000143	0.000584	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.000143	0.00181	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000142	0.00058	CcSEcCtD
Tadalafil—Oedema—Metformin—type 2 diabetes mellitus	0.000142	0.00058	CcSEcCtD
Tadalafil—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000142	0.000579	CcSEcCtD
Tadalafil—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000142	0.000579	CcSEcCtD
Tadalafil—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000141	0.000578	CcSEcCtD
Tadalafil—Flushing—Ramipril—type 2 diabetes mellitus	0.000141	0.000577	CcSEcCtD
Tadalafil—Angioedema—Losartan—type 2 diabetes mellitus	0.000141	0.000577	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.000141	0.00179	CbGpPWpGaD
Tadalafil—Infection—Metformin—type 2 diabetes mellitus	0.000141	0.000576	CcSEcCtD
Tadalafil—Insomnia—Valsartan—type 2 diabetes mellitus	0.000141	0.000576	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.000141	0.00179	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—MMP1—type 2 diabetes mellitus	0.00014	0.00179	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.00014	0.000573	CcSEcCtD
Tadalafil—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.00014	0.000572	CcSEcCtD
Tadalafil—Myalgia—Irbesartan—type 2 diabetes mellitus	0.00014	0.000571	CcSEcCtD
Tadalafil—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.00014	0.000571	CcSEcCtD
Tadalafil—Chest pain—Irbesartan—type 2 diabetes mellitus	0.00014	0.000571	CcSEcCtD
Tadalafil—Shock—Metformin—type 2 diabetes mellitus	0.000139	0.00057	CcSEcCtD
Tadalafil—Insomnia—Orlistat—type 2 diabetes mellitus	0.000139	0.000569	CcSEcCtD
Tadalafil—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000139	0.000569	CcSEcCtD
Tadalafil—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000139	0.000569	CcSEcCtD
Tadalafil—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000139	0.000568	CcSEcCtD
Tadalafil—Vertigo—Losartan—type 2 diabetes mellitus	0.000139	0.000567	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000139	0.000567	CcSEcCtD
Tadalafil—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000139	0.000567	CcSEcCtD
Tadalafil—Somnolence—Valsartan—type 2 diabetes mellitus	0.000138	0.000566	CcSEcCtD
Tadalafil—Syncope—Losartan—type 2 diabetes mellitus	0.000138	0.000566	CcSEcCtD
Tadalafil—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000138	0.000565	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—GIP—type 2 diabetes mellitus	0.000138	0.00176	CbGpPWpGaD
Tadalafil—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000138	0.000564	CcSEcCtD
Tadalafil—Skin disorder—Metformin—type 2 diabetes mellitus	0.000138	0.000563	CcSEcCtD
Tadalafil—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000137	0.000561	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—CD36—type 2 diabetes mellitus	0.000137	0.00175	CbGpPWpGaD
Tadalafil—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000137	0.000561	CcSEcCtD
Tadalafil—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000137	0.00056	CcSEcCtD
Tadalafil—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000137	0.00056	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.000137	0.00174	CbGpPWpGaD
Tadalafil—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000136	0.000558	CcSEcCtD
Tadalafil—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000136	0.000558	CcSEcCtD
Tadalafil—Palpitations—Losartan—type 2 diabetes mellitus	0.000136	0.000558	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—CALM1—type 2 diabetes mellitus	0.000136	0.00173	CbGpPWpGaD
Tadalafil—Nausea—Glimepiride—type 2 diabetes mellitus	0.000136	0.000556	CcSEcCtD
Tadalafil—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000136	0.000555	CcSEcCtD
Tadalafil—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000135	0.000554	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—PPP2CA—type 2 diabetes mellitus	0.000135	0.00172	CbGpPWpGaD
Tadalafil—CYP3A4—Constitutive Androstane Receptor Pathway—PPARGC1A—type 2 diabetes mellitus	0.000135	0.00172	CbGpPWpGaD
Tadalafil—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000135	0.000554	CcSEcCtD
Tadalafil—Asthenia—Glyburide—type 2 diabetes mellitus	0.000135	0.000554	CcSEcCtD
Tadalafil—Cough—Losartan—type 2 diabetes mellitus	0.000135	0.000551	CcSEcCtD
Tadalafil—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000135	0.000551	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000134	0.00055	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—APOA1—type 2 diabetes mellitus	0.000134	0.00171	CbGpPWpGaD
Tadalafil—Fatigue—Valsartan—type 2 diabetes mellitus	0.000134	0.000549	CcSEcCtD
Tadalafil—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000134	0.000548	CcSEcCtD
Tadalafil—Oedema—Irbesartan—type 2 diabetes mellitus	0.000134	0.000547	CcSEcCtD
Tadalafil—Pruritus—Glyburide—type 2 diabetes mellitus	0.000133	0.000546	CcSEcCtD
Tadalafil—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000133	0.000545	CcSEcCtD
Tadalafil—Constipation—Valsartan—type 2 diabetes mellitus	0.000133	0.000545	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000133	0.00169	CbGpPWpGaD
Tadalafil—Infection—Irbesartan—type 2 diabetes mellitus	0.000133	0.000544	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000133	0.000543	CcSEcCtD
Tadalafil—Fatigue—Orlistat—type 2 diabetes mellitus	0.000133	0.000542	CcSEcCtD
Tadalafil—Hypotension—Metformin—type 2 diabetes mellitus	0.000132	0.000542	CcSEcCtD
Tadalafil—Shock—Irbesartan—type 2 diabetes mellitus	0.000132	0.000538	CcSEcCtD
Tadalafil—Pain—Orlistat—type 2 diabetes mellitus	0.000132	0.000538	CcSEcCtD
Tadalafil—Chest pain—Losartan—type 2 diabetes mellitus	0.000131	0.000537	CcSEcCtD
Tadalafil—Arthralgia—Losartan—type 2 diabetes mellitus	0.000131	0.000537	CcSEcCtD
Tadalafil—Myalgia—Losartan—type 2 diabetes mellitus	0.000131	0.000537	CcSEcCtD
Tadalafil—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000131	0.000537	CcSEcCtD
Tadalafil—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000131	0.000537	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.000131	0.00167	CbGpPWpGaD
Tadalafil—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000131	0.000534	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.00013	0.00166	CbGpPWpGaD
Tadalafil—Rash—Bromocriptine—type 2 diabetes mellitus	0.00013	0.000532	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.00013	0.00166	CbGpPWpGaD
Tadalafil—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.00013	0.000532	CcSEcCtD
Tadalafil—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00013	0.000532	CcSEcCtD
Tadalafil—Discomfort—Losartan—type 2 diabetes mellitus	0.00013	0.000531	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.00013	0.00165	CbGpPWpGaD
Tadalafil—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000129	0.000529	CcSEcCtD
Tadalafil—Headache—Bromocriptine—type 2 diabetes mellitus	0.000129	0.000529	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000129	0.000528	CcSEcCtD
Tadalafil—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000129	0.000528	CcSEcCtD
Tadalafil—Dry mouth—Losartan—type 2 diabetes mellitus	0.000128	0.000525	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.000128	0.00163	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PRKCB—type 2 diabetes mellitus	0.000128	0.00163	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.000128	0.00163	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000127	0.000521	CcSEcCtD
Tadalafil—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000127	0.000521	CcSEcCtD
Tadalafil—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000127	0.00052	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—NOS2—type 2 diabetes mellitus	0.000127	0.00161	CbGpPWpGaD
Tadalafil—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000126	0.000517	CcSEcCtD
Tadalafil—Somnolence—Metformin—type 2 diabetes mellitus	0.000126	0.000515	CcSEcCtD
Tadalafil—Oedema—Losartan—type 2 diabetes mellitus	0.000126	0.000515	CcSEcCtD
Tadalafil—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000126	0.000514	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	0.000125	0.00159	CbGpPWpGaD
Tadalafil—Infection—Losartan—type 2 diabetes mellitus	0.000125	0.000512	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—MMP1—type 2 diabetes mellitus	0.000125	0.00159	CbGpPWpGaD
Tadalafil—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000125	0.000511	CcSEcCtD
Tadalafil—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000125	0.000511	CcSEcCtD
Tadalafil—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000125	0.00051	CcSEcCtD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP2E1—type 2 diabetes mellitus	0.000124	0.00158	CbGpPWpGaD
Tadalafil—Shock—Losartan—type 2 diabetes mellitus	0.000124	0.000507	CcSEcCtD
Tadalafil—Urticaria—Valsartan—type 2 diabetes mellitus	0.000124	0.000506	CcSEcCtD
Tadalafil—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000123	0.000505	CcSEcCtD
Tadalafil—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000123	0.000503	CcSEcCtD
Tadalafil—Tachycardia—Losartan—type 2 diabetes mellitus	0.000123	0.000503	CcSEcCtD
Tadalafil—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000123	0.000501	CcSEcCtD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP1A2—type 2 diabetes mellitus	0.000123	0.00156	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000122	0.000501	CcSEcCtD
Tadalafil—Fatigue—Metformin—type 2 diabetes mellitus	0.000122	0.0005	CcSEcCtD
Tadalafil—Urticaria—Orlistat—type 2 diabetes mellitus	0.000122	0.0005	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000122	0.000499	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TLE4—type 2 diabetes mellitus	0.000122	0.00155	CbGpPWpGaD
Tadalafil—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000122	0.000498	CcSEcCtD
Tadalafil—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000122	0.000497	CcSEcCtD
Tadalafil—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000122	0.000497	CcSEcCtD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	0.000121	0.00155	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—CALM1—type 2 diabetes mellitus	0.000121	0.00155	CbGpPWpGaD
Tadalafil—Constipation—Metformin—type 2 diabetes mellitus	0.000121	0.000496	CcSEcCtD
Tadalafil—Angioedema—Ramipril—type 2 diabetes mellitus	0.000121	0.000494	CcSEcCtD
Tadalafil—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.00012	0.000491	CcSEcCtD
Tadalafil—Vomiting—Glyburide—type 2 diabetes mellitus	0.00012	0.000491	CcSEcCtD
Tadalafil—Pruritus—Gliclazide—type 2 diabetes mellitus	0.00012	0.00049	CcSEcCtD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	0.00012	0.00153	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—APOA1—type 2 diabetes mellitus	0.00012	0.00152	CbGpPWpGaD
Tadalafil—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000119	0.000488	CcSEcCtD
Tadalafil—Rash—Glyburide—type 2 diabetes mellitus	0.000119	0.000487	CcSEcCtD
Tadalafil—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000119	0.000486	CcSEcCtD
Tadalafil—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000119	0.000486	CcSEcCtD
Tadalafil—Vertigo—Ramipril—type 2 diabetes mellitus	0.000119	0.000486	CcSEcCtD
Tadalafil—Syncope—Ramipril—type 2 diabetes mellitus	0.000119	0.000485	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—GCG—type 2 diabetes mellitus	0.000118	0.00151	CbGpPWpGaD
Tadalafil—Headache—Glyburide—type 2 diabetes mellitus	0.000118	0.000484	CcSEcCtD
Tadalafil—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000118	0.000482	CcSEcCtD
Tadalafil—Hypotension—Losartan—type 2 diabetes mellitus	0.000118	0.000481	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ADRB3—type 2 diabetes mellitus	0.000117	0.00149	CbGpPWpGaD
Tadalafil—Palpitations—Ramipril—type 2 diabetes mellitus	0.000117	0.000478	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	0.000117	0.00148	CbGpPWpGaD
Tadalafil—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000116	0.000476	CcSEcCtD
Tadalafil—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000116	0.000474	CcSEcCtD
Tadalafil—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000116	0.000474	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000115	0.000472	CcSEcCtD
Tadalafil—Cough—Ramipril—type 2 diabetes mellitus	0.000115	0.000472	CcSEcCtD
Tadalafil—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000115	0.000472	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000115	0.000469	CcSEcCtD
Tadalafil—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000115	0.000469	CcSEcCtD
Tadalafil—Convulsion—Ramipril—type 2 diabetes mellitus	0.000115	0.000469	CcSEcCtD
Tadalafil—Constipation—Irbesartan—type 2 diabetes mellitus	0.000114	0.000468	CcSEcCtD
Tadalafil—Pain—Irbesartan—type 2 diabetes mellitus	0.000114	0.000468	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—PRKCB—type 2 diabetes mellitus	0.000114	0.00145	CbGpPWpGaD
Tadalafil—Insomnia—Losartan—type 2 diabetes mellitus	0.000114	0.000466	CcSEcCtD
Tadalafil—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000113	0.000464	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CRHR1—type 2 diabetes mellitus	0.000113	0.00144	CbGpPWpGaD
Tadalafil—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000113	0.000462	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—NOS2—type 2 diabetes mellitus	0.000113	0.00143	CbGpPWpGaD
Tadalafil—Urticaria—Metformin—type 2 diabetes mellitus	0.000113	0.000461	CcSEcCtD
Tadalafil—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000113	0.000461	CcSEcCtD
Tadalafil—Chest pain—Ramipril—type 2 diabetes mellitus	0.000113	0.000461	CcSEcCtD
Tadalafil—Myalgia—Ramipril—type 2 diabetes mellitus	0.000113	0.000461	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	0.000112	0.00143	CbGpPWpGaD
Tadalafil—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000112	0.000459	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—IGF1—type 2 diabetes mellitus	0.000112	0.00143	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—AKT2—type 2 diabetes mellitus	0.000112	0.00143	CbGpPWpGaD
Tadalafil—Nausea—Glyburide—type 2 diabetes mellitus	0.000112	0.000458	CcSEcCtD
Tadalafil—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000112	0.000458	CcSEcCtD
Tadalafil—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000112	0.000458	CcSEcCtD
Tadalafil—Somnolence—Losartan—type 2 diabetes mellitus	0.000112	0.000458	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000112	0.000457	CcSEcCtD
Tadalafil—Asthenia—Valsartan—type 2 diabetes mellitus	0.000112	0.000457	CcSEcCtD
Tadalafil—Discomfort—Ramipril—type 2 diabetes mellitus	0.000111	0.000455	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—AVP—type 2 diabetes mellitus	0.000111	0.00141	CbGpPWpGaD
Tadalafil—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000111	0.000453	CcSEcCtD
Tadalafil—Asthenia—Orlistat—type 2 diabetes mellitus	0.00011	0.000451	CcSEcCtD
Tadalafil—Pruritus—Valsartan—type 2 diabetes mellitus	0.00011	0.00045	CcSEcCtD
Tadalafil—Dry mouth—Ramipril—type 2 diabetes mellitus	0.00011	0.00045	CcSEcCtD
Tadalafil—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000109	0.000447	CcSEcCtD
Tadalafil—Pruritus—Orlistat—type 2 diabetes mellitus	0.000109	0.000445	CcSEcCtD
Tadalafil—Fatigue—Losartan—type 2 diabetes mellitus	0.000109	0.000444	CcSEcCtD
Tadalafil—Oedema—Ramipril—type 2 diabetes mellitus	0.000108	0.000442	CcSEcCtD
Tadalafil—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000108	0.000441	CcSEcCtD
Tadalafil—Pain—Losartan—type 2 diabetes mellitus	0.000108	0.00044	CcSEcCtD
Tadalafil—Constipation—Losartan—type 2 diabetes mellitus	0.000108	0.00044	CcSEcCtD
Tadalafil—Rash—Gliclazide—type 2 diabetes mellitus	0.000107	0.000437	CcSEcCtD
Tadalafil—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000107	0.000437	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—SERPINE1—type 2 diabetes mellitus	0.000107	0.00136	CbGpPWpGaD
Tadalafil—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000107	0.000436	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—MAT1A—type 2 diabetes mellitus	0.000106	0.00135	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—ALB—type 2 diabetes mellitus	0.000106	0.00135	CbGpPWpGaD
Tadalafil—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000106	0.000435	CcSEcCtD
Tadalafil—Shock—Ramipril—type 2 diabetes mellitus	0.000106	0.000434	CcSEcCtD
Tadalafil—Headache—Gliclazide—type 2 diabetes mellitus	0.000106	0.000434	CcSEcCtD
Tadalafil—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000106	0.000433	CcSEcCtD
Tadalafil—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000106	0.000433	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	0.000105	0.00134	CbGpPWpGaD
Tadalafil—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000105	0.000431	CcSEcCtD
Tadalafil—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000105	0.00043	CcSEcCtD
Tadalafil—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000105	0.000429	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	0.000105	0.00133	CbGpPWpGaD
Tadalafil—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000104	0.000427	CcSEcCtD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	0.000104	0.00132	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SPRY2—type 2 diabetes mellitus	0.000104	0.00132	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	0.000104	0.00132	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000103	0.000421	CcSEcCtD
Tadalafil—Dizziness—Valsartan—type 2 diabetes mellitus	0.000103	0.000421	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—GNB3—type 2 diabetes mellitus	0.000102	0.0013	CbGpPWpGaD
Tadalafil—Dizziness—Orlistat—type 2 diabetes mellitus	0.000102	0.000416	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—PIK3R1—type 2 diabetes mellitus	0.000102	0.00129	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—NOS3—type 2 diabetes mellitus	0.000102	0.00129	CbGpPWpGaD
Tadalafil—Asthenia—Metformin—type 2 diabetes mellitus	0.000102	0.000416	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—RBP4—type 2 diabetes mellitus	0.000101	0.00128	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GLP1R—type 2 diabetes mellitus	0.000101	0.00128	CbGpPWpGaD
Tadalafil—Hypotension—Ramipril—type 2 diabetes mellitus	0.000101	0.000413	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—AVP—type 2 diabetes mellitus	0.000101	0.00128	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—MMP3—type 2 diabetes mellitus	0.000101	0.00128	CbGpPWpGaD
Tadalafil—Nausea—Gliclazide—type 2 diabetes mellitus	0.000101	0.000412	CcSEcCtD
Tadalafil—Pruritus—Metformin—type 2 diabetes mellitus	0.0001	0.00041	CcSEcCtD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	0.0001	0.00128	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	0.0001	0.00128	CbGpPWpGaD
Tadalafil—Urticaria—Losartan—type 2 diabetes mellitus	0.0001	0.000409	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—IGF1—type 2 diabetes mellitus	0.0001	0.00127	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—AKT2—type 2 diabetes mellitus	9.99e-05	0.00127	CbGpPWpGaD
Tadalafil—Abdominal pain—Losartan—type 2 diabetes mellitus	9.95e-05	0.000407	CcSEcCtD
Tadalafil—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	9.95e-05	0.00127	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCKAR—type 2 diabetes mellitus	9.93e-05	0.00126	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	9.91e-05	0.00126	CbGpPWpGaD
Tadalafil—Vomiting—Valsartan—type 2 diabetes mellitus	9.9e-05	0.000405	CcSEcCtD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	9.89e-05	0.00126	CbGpPWpGaD
Tadalafil—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	9.86e-05	0.000403	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	9.84e-05	0.00125	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	9.84e-05	0.000402	CcSEcCtD
Tadalafil—Rash—Valsartan—type 2 diabetes mellitus	9.82e-05	0.000401	CcSEcCtD
Tadalafil—Dermatitis—Valsartan—type 2 diabetes mellitus	9.81e-05	0.000401	CcSEcCtD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	9.78e-05	0.00124	CbGpPWpGaD
Tadalafil—Vomiting—Orlistat—type 2 diabetes mellitus	9.78e-05	0.0004	CcSEcCtD
Tadalafil—Insomnia—Ramipril—type 2 diabetes mellitus	9.76e-05	0.000399	CcSEcCtD
Tadalafil—Headache—Valsartan—type 2 diabetes mellitus	9.75e-05	0.000399	CcSEcCtD
Tadalafil—Diarrhoea—Metformin—type 2 diabetes mellitus	9.7e-05	0.000397	CcSEcCtD
Tadalafil—Rash—Orlistat—type 2 diabetes mellitus	9.7e-05	0.000397	CcSEcCtD
Tadalafil—Paraesthesia—Ramipril—type 2 diabetes mellitus	9.69e-05	0.000397	CcSEcCtD
Tadalafil—Dermatitis—Orlistat—type 2 diabetes mellitus	9.69e-05	0.000396	CcSEcCtD
Tadalafil—Headache—Orlistat—type 2 diabetes mellitus	9.64e-05	0.000394	CcSEcCtD
Tadalafil—Dyspnoea—Ramipril—type 2 diabetes mellitus	9.62e-05	0.000394	CcSEcCtD
Tadalafil—Asthenia—Irbesartan—type 2 diabetes mellitus	9.6e-05	0.000393	CcSEcCtD
Tadalafil—Somnolence—Ramipril—type 2 diabetes mellitus	9.6e-05	0.000393	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—EDN1—type 2 diabetes mellitus	9.58e-05	0.00122	CbGpPWpGaD
Tadalafil—Dyspepsia—Ramipril—type 2 diabetes mellitus	9.5e-05	0.000389	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—SERPINE1—type 2 diabetes mellitus	9.5e-05	0.00121	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—ALB—type 2 diabetes mellitus	9.48e-05	0.00121	CbGpPWpGaD
Tadalafil—Pruritus—Irbesartan—type 2 diabetes mellitus	9.46e-05	0.000387	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	9.43e-05	0.0012	CbGpPWpGaD
Tadalafil—Dizziness—Metformin—type 2 diabetes mellitus	9.37e-05	0.000383	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	9.32e-05	0.000381	CcSEcCtD
Tadalafil—Fatigue—Ramipril—type 2 diabetes mellitus	9.31e-05	0.000381	CcSEcCtD
Tadalafil—Hypersensitivity—Losartan—type 2 diabetes mellitus	9.28e-05	0.000379	CcSEcCtD
Tadalafil—Nausea—Valsartan—type 2 diabetes mellitus	9.25e-05	0.000378	CcSEcCtD
Tadalafil—Constipation—Ramipril—type 2 diabetes mellitus	9.23e-05	0.000378	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—C3—type 2 diabetes mellitus	9.22e-05	0.00117	CbGpPWpGaD
Tadalafil—Diarrhoea—Irbesartan—type 2 diabetes mellitus	9.15e-05	0.000374	CcSEcCtD
Tadalafil—Nausea—Orlistat—type 2 diabetes mellitus	9.14e-05	0.000374	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	9.1e-05	0.00116	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3R1—type 2 diabetes mellitus	9.07e-05	0.00115	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—NOS3—type 2 diabetes mellitus	9.07e-05	0.00115	CbGpPWpGaD
Tadalafil—Asthenia—Losartan—type 2 diabetes mellitus	9.03e-05	0.000369	CcSEcCtD
Tadalafil—Vomiting—Metformin—type 2 diabetes mellitus	9.01e-05	0.000369	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	9e-05	0.00115	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IAPP—type 2 diabetes mellitus	8.94e-05	0.00114	CbGpPWpGaD
Tadalafil—Rash—Metformin—type 2 diabetes mellitus	8.94e-05	0.000366	CcSEcCtD
Tadalafil—Dermatitis—Metformin—type 2 diabetes mellitus	8.93e-05	0.000365	CcSEcCtD
Tadalafil—Pruritus—Losartan—type 2 diabetes mellitus	8.91e-05	0.000364	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—INSR—type 2 diabetes mellitus	8.89e-05	0.00113	CbGpPWpGaD
Tadalafil—Headache—Metformin—type 2 diabetes mellitus	8.88e-05	0.000363	CcSEcCtD
Tadalafil—Dizziness—Irbesartan—type 2 diabetes mellitus	8.85e-05	0.000362	CcSEcCtD
Tadalafil—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	8.83e-05	0.000361	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—AGT—type 2 diabetes mellitus	8.76e-05	0.00111	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	8.73e-05	0.00111	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	8.72e-05	0.00111	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	8.68e-05	0.0011	CbGpPWpGaD
Tadalafil—Diarrhoea—Losartan—type 2 diabetes mellitus	8.61e-05	0.000352	CcSEcCtD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	8.58e-05	0.00109	CbGpPWpGaD
Tadalafil—Urticaria—Ramipril—type 2 diabetes mellitus	8.58e-05	0.000351	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	8.56e-05	0.00109	CbGpPWpGaD
Tadalafil—Abdominal pain—Ramipril—type 2 diabetes mellitus	8.53e-05	0.000349	CcSEcCtD
Tadalafil—Vomiting—Irbesartan—type 2 diabetes mellitus	8.51e-05	0.000348	CcSEcCtD
Tadalafil—Rash—Irbesartan—type 2 diabetes mellitus	8.43e-05	0.000345	CcSEcCtD
Tadalafil—Dermatitis—Irbesartan—type 2 diabetes mellitus	8.43e-05	0.000345	CcSEcCtD
Tadalafil—Nausea—Metformin—type 2 diabetes mellitus	8.42e-05	0.000344	CcSEcCtD
Tadalafil—Headache—Irbesartan—type 2 diabetes mellitus	8.38e-05	0.000343	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—C3—type 2 diabetes mellitus	8.37e-05	0.00107	CbGpPWpGaD
Tadalafil—Dizziness—Losartan—type 2 diabetes mellitus	8.33e-05	0.000341	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	8.31e-05	0.00106	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	8.13e-05	0.00103	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	8.09e-05	0.00103	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	8.07e-05	0.00103	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	8.07e-05	0.00103	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	8.04e-05	0.00102	CbGpPWpGaD
Tadalafil—Vomiting—Losartan—type 2 diabetes mellitus	8e-05	0.000327	CcSEcCtD
Tadalafil—Hypersensitivity—Ramipril—type 2 diabetes mellitus	7.95e-05	0.000325	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—AGT—type 2 diabetes mellitus	7.95e-05	0.00101	CbGpPWpGaD
Tadalafil—Nausea—Irbesartan—type 2 diabetes mellitus	7.95e-05	0.000325	CcSEcCtD
Tadalafil—Rash—Losartan—type 2 diabetes mellitus	7.94e-05	0.000325	CcSEcCtD
Tadalafil—Dermatitis—Losartan—type 2 diabetes mellitus	7.93e-05	0.000324	CcSEcCtD
Tadalafil—Headache—Losartan—type 2 diabetes mellitus	7.89e-05	0.000323	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	7.85e-05	0.000999	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	7.82e-05	0.000995	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CYBA—type 2 diabetes mellitus	7.82e-05	0.000995	CbGpPWpGaD
Tadalafil—Asthenia—Ramipril—type 2 diabetes mellitus	7.75e-05	0.000317	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	7.68e-05	0.000978	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GHRL—type 2 diabetes mellitus	7.65e-05	0.000974	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PLAT—type 2 diabetes mellitus	7.65e-05	0.000974	CbGpPWpGaD
Tadalafil—Pruritus—Ramipril—type 2 diabetes mellitus	7.64e-05	0.000312	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.56e-05	0.000962	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—SRC—type 2 diabetes mellitus	7.52e-05	0.000957	CbGpPWpGaD
Tadalafil—Nausea—Losartan—type 2 diabetes mellitus	7.48e-05	0.000306	CcSEcCtD
Tadalafil—Diarrhoea—Ramipril—type 2 diabetes mellitus	7.39e-05	0.000302	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	7.35e-05	0.000935	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—VEGFA—type 2 diabetes mellitus	7.33e-05	0.000932	CbGpPWpGaD
Tadalafil—Dizziness—Ramipril—type 2 diabetes mellitus	7.14e-05	0.000292	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	7.12e-05	0.000906	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	7.08e-05	0.000902	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	7e-05	0.00089	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GCG—type 2 diabetes mellitus	7e-05	0.00089	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.88e-05	0.000876	CbGpPWpGaD
Tadalafil—Vomiting—Ramipril—type 2 diabetes mellitus	6.86e-05	0.000281	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.86e-05	0.000873	CbGpPWpGaD
Tadalafil—Rash—Ramipril—type 2 diabetes mellitus	6.81e-05	0.000278	CcSEcCtD
Tadalafil—Dermatitis—Ramipril—type 2 diabetes mellitus	6.8e-05	0.000278	CcSEcCtD
Tadalafil—Headache—Ramipril—type 2 diabetes mellitus	6.76e-05	0.000277	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—TGFB1—type 2 diabetes mellitus	6.73e-05	0.000856	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—SRC—type 2 diabetes mellitus	6.71e-05	0.000853	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.55e-05	0.000833	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—VEGFA—type 2 diabetes mellitus	6.53e-05	0.000831	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.43e-05	0.000819	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.43e-05	0.000818	CbGpPWpGaD
Tadalafil—Nausea—Ramipril—type 2 diabetes mellitus	6.41e-05	0.000262	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.09e-05	0.000775	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.03e-05	0.000768	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—TGFB1—type 2 diabetes mellitus	5.99e-05	0.000763	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AVP—type 2 diabetes mellitus	5.95e-05	0.000757	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.95e-05	0.000757	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.92e-05	0.000754	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.9e-05	0.000751	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.84e-05	0.000743	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APOB—type 2 diabetes mellitus	5.75e-05	0.000732	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.73e-05	0.000729	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.66e-05	0.00072	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LPL—type 2 diabetes mellitus	5.49e-05	0.000699	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	5.4e-05	0.000687	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.38e-05	0.000684	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	5.23e-05	0.000665	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	5.16e-05	0.000656	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.15e-05	0.000656	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.06e-05	0.000644	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—C3—type 2 diabetes mellitus	4.94e-05	0.000629	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.72e-05	0.0006	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.7e-05	0.000599	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.7e-05	0.000598	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—AKT1—type 2 diabetes mellitus	4.68e-05	0.000595	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.62e-05	0.000588	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.6e-05	0.000586	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.6e-05	0.000586	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.55e-05	0.000579	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.34e-05	0.000552	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	4.32e-05	0.000549	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	4.27e-05	0.000543	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	4.26e-05	0.000542	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	4.21e-05	0.000536	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—AKT1—type 2 diabetes mellitus	4.17e-05	0.00053	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.11e-05	0.000523	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—INS—type 2 diabetes mellitus	3.93e-05	0.0005	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.87e-05	0.000492	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.8e-05	0.000484	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.8e-05	0.000484	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.78e-05	0.000482	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.61e-05	0.00046	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.45e-05	0.000439	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.45e-05	0.000439	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	3.27e-05	0.000416	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.25e-05	0.000413	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	3.23e-05	0.000411	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.95e-05	0.000376	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.93e-05	0.000373	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.91e-05	0.00037	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.77e-05	0.000352	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.74e-05	0.000348	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.68e-05	0.000341	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.55e-05	0.000325	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	2.5e-05	0.000318	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.48e-05	0.000316	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.28e-05	0.00029	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.24e-05	0.000284	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	2.18e-05	0.000278	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	2.18e-05	0.000278	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	2.07e-05	0.000263	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	2.07e-05	0.000263	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.97e-05	0.000251	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.82e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.82e-05	0.000232	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.76e-05	0.000224	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.76e-05	0.000224	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.76e-05	0.000224	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.76e-05	0.000224	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.76e-05	0.000224	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.72e-05	0.000219	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.7e-05	0.000217	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.61e-05	0.000205	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.61e-05	0.000205	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.59e-05	0.000202	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.57e-05	0.000199	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.49e-05	0.00019	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.49e-05	0.00019	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.49e-05	0.00019	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.43e-05	0.000182	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.43e-05	0.000182	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.38e-05	0.000176	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.38e-05	0.000176	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.36e-05	0.000172	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.33e-05	0.00017	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.33e-05	0.00017	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.33e-05	0.00017	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.25e-05	0.000159	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.17e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.13e-05	0.000144	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.13e-05	0.000144	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.13e-05	0.000144	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.13e-05	0.000144	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.09e-05	0.000138	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.01e-05	0.000128	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	9.43e-06	0.00012	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	9.23e-06	0.000118	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	9.23e-06	0.000118	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	9.06e-06	0.000115	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	9e-06	0.000115	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	9e-06	0.000115	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	9e-06	0.000115	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	8.94e-06	0.000114	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	8.78e-06	0.000112	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	8.68e-06	0.00011	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	8.07e-06	0.000103	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	8.07e-06	0.000103	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	8.07e-06	0.000103	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	7.92e-06	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	7.85e-06	9.99e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	7.68e-06	9.78e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	7.38e-06	9.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	7.3e-06	9.29e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	7.3e-06	9.29e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	7e-06	8.91e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	7e-06	8.91e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.03e-06	7.68e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	6.03e-06	7.68e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	6e-06	7.64e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.92e-06	7.54e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.75e-06	7.32e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	5.59e-06	7.12e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	5.49e-06	6.99e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	5.38e-06	6.84e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	5.36e-06	6.82e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	5.22e-06	6.64e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	5.15e-06	6.56e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.94e-06	6.29e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.85e-06	6.17e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.7e-06	5.98e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.62e-06	5.88e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.6e-06	5.86e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	4.55e-06	5.79e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	4.01e-06	5.1e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.93e-06	5e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.61e-06	4.59e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.45e-06	4.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.45e-06	4.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	3.15e-06	4.01e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.59e-06	2.02e-05	CbGpPWpGaD
